Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration
- 12 January 2024
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 16 (10) , 1167-1181
Abstract
FG‐4592 is a hypoxia‐inducible factor inhibitor that has been approved for therapeutic use in some countries. This class of compounds can increase the oxygen carrying capacity of the blood and thus have the potential to be used as performance enhancing agents in sports. The purpose of this study was to investigate the detection of FG‐4592 and metabolites in equine plasma and mane hair following a multiple dose oral administration to two Thoroughbred racehorses, to identify the best analytical targets for doping control laboratories. Urine samples were also analysed, and the results compared to previously published urine data. Liquid chromatography‐high resolution mass spectrometry was used for metabolite identification in urine and plasma. Liquid chromatography–tandem mass spectrometry was used for full sample analysis of urine, plasma and hair samples and generation of urine and plasma profiles. FG‐4592 and a mono‐hydroxylated metabolite were detected in plasma. FG‐4592 was detected with the greatest abundance and gave the longest duration of detection, up to 312 h post‐administration, and would be the recommended target in routine doping samples. FG‐4592 was detected in all mane hair samples collected post‐administration, up to 166 days following the final dose, showing extended detection can be achieved with this matrix. To the best of the authors' knowledge, this is the first report of FG‐4592 and metabolites in equine plasma and hair samples. Urine results were consistent with the previously published data, with FG‐4592 offering the best target for detection and longest detection periods.Keywords
This publication has 20 references indexed in Scilit:
- lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG‐4592) and its main metabolites into routine doping controlsDrug Testing and Analysis, 2017
- Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2017
- Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDClinical Journal of the American Society of Nephrology, 2016
- Detection by LC–MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive caseJournal of Pharmaceutical and Biomedical Analysis, 2016
- Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKDJournal of Pharmacological Sciences, 2009
- Differentiation between drug use and environmental contamination when testing for drugs in hairForensic Science International, 2008
- Hydroxylation of Hypoxia-Inducible Transcription Factors and Chemical Compounds Targeting the HIF-α HydroxylasesCurrent Medicinal Chemistry, 2007
- A Conserved Family of Prolyl-4-Hydroxylases That Modify HIFScience, 2001
- Deposition of 7-Aminoflunitrazepam and Flunitrazepam in Hair After a Single Dose of Rohypnol®Journal of Forensic Sciences, 2001
- Quantitation of Clonazepam and Its Major Metabolite 7-Aminoclonazepam in HairJournal of Analytical Toxicology, 2000